Table 1.
Demographic and clinical characteristics
| Age (yrs) | 65.7 (5.7) |
| Height (cm) | 177.1 (7.2) |
| Weight (kg) | 81.6 (15.7) |
| ABI‐most affected leg | 0.69 (0.1) |
| ABI‐other leg | 0.92 (0.2) |
| BMI (kg/m2) | 25.8 (3.8) |
| Systolic blood pressure (mmHg) | 136.2 (13.5) |
| Diastolic blood pressure (mmHg) | 74.7 (9.8) |
| FVC (L) | 3.85 (0.85) |
| FEV1 (L) | 2.84 (0.64) |
| FEV1 (%pred) | 87.25 (13.45) |
| FEV1/FVC | 73.88 (7.04) |
| Sex, n (%) | |
| Male | 14 (87.5) |
| Female | 2 (12.5) |
| Most symptomatic leg, n (%) | |
| Left | 8 (50.0) |
| Right | 8 (50.0) |
| Stents, n (%) | |
| No | 11 (68.7) |
| Yes | 5 (31.2) |
| Smoking status, n (%) | |
| Never smoked | 1 (6.2) |
| Current smoker | 9 (56.2) |
| Past smoker | 6 (37.5) |
| Diabetes, n (%) | |
| No | 15 (93.7) |
| Yes | 1 (6.2) |
| Race, n (%) | |
| Black/African American | 4 (25.0) |
| White | 12 (75.0) |
| Medications, n (%) | |
| Beta Blocker | 5 (31.2) |
| ACE Inhibitor | 4 (25.0) |
| Statin | 12 (75.0) |
| Cilostazol | 5 (31.2) |
| Calcium Channel Blocker | 6 (37.5) |
| Diuretic | 3 (18.7) |
| Anti‐Platelet Agent | 3 (18.7) |
| Angiotensin II Receptor Antagonist | 2 (12.5) |
| Opioid | 4 (25.0) |
| Other | 15 (93.7) |
Values are as means ± SD or n (%) when indicated. ABI, ankle‐brachial index; BMI, body mass index; ACE, angiotensin‐converting enzyme; FVC, forced vital capacity; FEV1, forced expiratory volume in 1 s; FEV1 (%pred), % predicted forced expiratory volume in 1 s.